Equity Research, Broker Reports, and media content on Formycon AG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Formycon AG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Formycon AG

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Formycon AG. We currently have 13 research reports from 1 professional analysts.

Date Source Announcement
16Aug22 06:30 EQS-News DGAP-News: Formycons Ustekinumab Biosimilar-Kandidat FYB202 zeigt in Phase-III-Studie vergleichbare Wirksamkeit zum Referenzprodukt Stelara®*
16Aug22 06:30 EQS-News DGAP-News: Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study
05Aug22 16:09 DGAP-AHD DGAP-DD: Formycon AG english
05Aug22 16:09 DGAP-AHD DGAP-DD: Formycon AG deutsch
03Aug22 06:50 DGAP-AHD DGAP-Adhoc: Formycon gibt FDA-Zulassung von FYB201/CIMERLITM1 (Ranibizumab-eqrn) als austauschbares Biosimilar für Lucentis®2 bekannt
03Aug22 06:50 DGAP-AHD DGAP-Adhoc: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
01Jul22 09:03 EQS-News DGAP-News: Formycon Reports on Virtual Annual General Meeting 2022
  • Frequency of research reports


  • Research reports on

    Formycon AG

  • Providers covering

    Formycon AG